Envestnet Portfolio Solutions Inc. Sells 2,635 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Envestnet Portfolio Solutions Inc. cut its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 20.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,468 shares of the company’s stock after selling 2,635 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Teva Pharmaceutical Industries were worth $231,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the company. Stifel Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. increased its holdings in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after purchasing an additional 33,277 shares during the period. Sio Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $24,314,000. Pinnbrook Capital Management LP bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $4,966,000. Finally, Asset Management One Co. Ltd. grew its holdings in Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock worth $10,414,000 after acquiring an additional 58,413 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 2.8 %

Shares of NYSE:TEVA opened at $15.06 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a market capitalization of $17.07 billion, a PE ratio of -10.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The firm has a fifty day moving average of $17.21 and a 200 day moving average of $18.12. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on TEVA. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. Bank of America decreased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.